Vitamin B12 found to resolve somatosensory symptoms in diabetic neuropathy patients | All the latest medical news on the portal Medznat.ru. :- Medznat
EN | RU
EN | RU

Help Support

By clicking the "Submit" button, you accept the terms of the User Agreement, including those related to the processing of your personal data. More about data processing in the Policy.
Back

Vitamin B12 found to resolve somatosensory symptoms in diabetic neuropathy patients

Vitamin B12 found to resolve somatosensory symptoms in diabetic neuropathy patients Vitamin B12 found to resolve somatosensory symptoms in diabetic neuropathy patients
Vitamin B12 found to resolve somatosensory symptoms in diabetic neuropathy patients Vitamin B12 found to resolve somatosensory symptoms in diabetic neuropathy patients

What's new?

Oral dosage of 1000 μg of vitamin B12 daily found to be effective in improving sudomotor function, pain score, and QoL in patients with diabetic neuropathy.

Twelve months’ oral supplementation of vitamin B12 (Methylcobalamin) 1 mg is beneficial in increasing plasma B12 levels and improving all neurophysiological factors, sudomotor function, pain score, and quality of life of diabetic neuropathic patients (both peripheral and autonomic).

This prospective, double-blind, placebo-controlled trial of 90 patients with type-2 diabetes on metformin therapy for a minimum of 4 years examined the effect of regularizing vitamin B12 levels with vitamin B12 taken orally for a year. The active treatment group had 44 patients receiving B12 and control group had 46 patients receiving a placebo. These patients had >400 pmol/L B12 levels. The electrodiagnostic evaluation and cardiovascular autonomic reflex tests (CARTs) were performed. SUDOSCAN was used to calculate electrochemical skin conductance in hands and feet i.e. ESCH and ESCF. Quality of life and pain intensity was evaluated via the Michigan Neuropathy Screening Instrument Questionnaire and Examination (MNSIQ and MNSIE).

In the active group, vitamin B12 levels augmented from 232.0 ± 71.8 from initiation to 776.7 ± 242.3 pmol/L at follow-up, however not in the placebo group. Also, significant improvements were observed in the pain score, improved quality of life, VPT (vibration perception threshold), MNSIQ, sural nerve conduction velocity (SNCV), sural nerve action potential (SNAP), and ESCF in the active group but not in the control group. The CARTs and MNSIE did not improve significantly. No clinically significant adverse events were reported during the study.

Source:

Nutrients

Article:

Vitamin B12 Supplementation in Diabetic Neuropathy: A 1-Year, Randomized, Double-Blind, Placebo-Controlled Trial

Authors:

Triantafyllos Didangelos et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: